Whole-exome sequencing of gene CYP3A4 in Spanish participants receiving paclitaxel chemotherapy reported a trend towards higher treatment modifications in carriers of CYP3A4*22 (p = 0.066), but no statistically significant differences were observed for neuropathy grade and treatment modifications due to neuropathy (Apellaniz-Ruiz et al., 2015). The gene discussed is CYP3A4; the disease is neuropathy.